Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Autolus Therapeutics Ltd.. (3/3/16). "Press Release: Autolus Limited Appoints Chief Executive Officer – Dr. Christian Itin, Pioneer of T-cell Targeting Therapeutics, Takes the Helm of Europe’s Leading Engineered T-cell Developer". London.

Organisations Organisation Autolus Therapeutics Ltd.
  Today Autolus Therapeutics plc (Nasdaq: AUTL)
  Group Autolus Therapeutics plc (Nasdaq: AUTL)
  Organisation 2 Cytos Biotechnology AG
  Today Kuros Biosciences AG (SIX: KURN)
  Group Kuros (Group)
Products Product T cell therapy
  Product 2 blinatumomab (AMG 103/MT103/MEDI-538)
  Index term 2 Kuros–Cytos Biotechnology: investment, 201512–201601 reverse merger acquisition CHF160m of Kuros Biosurgery by Cytos to be renamed Kuros Biosciences
Persons Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
  Person 2 Hodgkin, Edward (Wellcome Trust 201304– Partner at Syncona Partners before CEO of Biotica Technology Ltd)

Autolus Limited (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, announced today that Dr Christian Itin will assume the role of Chief Executive Officer with immediate effect.

Dr Itin is a leader in the immuno-oncology field. Previously he served as President and CEO at Micromet Inc., a former NASDAQ-listed biopharmaceutical company, which was acquired in 2012 by Amgen. At Micromet, Dr Itin and his team pioneered the field of T-cell engaging antibodies, or BiTEs. The lead program, blinatumomab, obtained approval by the FDA as breakthrough therapy for the treatment of patients with acute lymphoblastic leukemia. Christian spent 13 years with Micromet in a number of senior management roles, becoming CEO in 2004. He continues to serve as Chairman of Autolus and Kuros Biosciences AG, and serves on the board of Kymab Ltd. From November 2012 to January 2016 he served as Chief Executive Officer and Chairman of Cytos Biotechnology Ltd.

Dr Edward Hodgkin, Partner with Syncona LLP, who has served as Chief Executive Officer of Autolus since its inception in September 2014, will transition to a Non-Executive Director role with immediate effect.

Edward Hodgkin commented:

“We’re fortunate to have attracted an individual of Christian’s calibre to lead Autolus. He brings the right qualities to manage the company through its next phase of growth, with products entering clinical development and a maturing technology platform providing strong differentiation over the competition. Christian is a leader in the field and Autolus will benefit greatly from his leadership.”

Christian Itin said:

“This is a great time to be taking over leadership of Autolus. The company has people of the highest quality, a strong operational base, and a pipeline of highly differentiated, innovative engineered T-cell products. Ed’s role as the start-up CEO illustrates the effectiveness of Syncona’s approach to fulfilling operational roles within their portfolio companies to provide a strong foundation for growth.”

Martin Pule, Founder and Chief Scientific Officer of Autolus, added:

“Christian has already made a tremendous impact through his role as Chairman. We are fortunate to have attracted him into the CEO role. He brings a unique expertise in the development and commercialisation of novel therapeutics which harness the considerable potency of T-cells. This appointment is a watershed moment for us, and Autolus is rapidly becoming a force to be reckoned with in the engineered T-cell field. This is in large part thanks to the careful stewardship of Syncona and Ed Hodgkin’s leadership.”

Autolus is founded upon the work of Dr Martin Pule, an academic clinical haematologist at University College London and a thought-leader in T-cell engineering. It is a next-generation engineered T-cell company, developing a series of T-cell products based on its proprietary targets, constructs and technologies.

– Ends –

Further information:

JW Communications
Julia Wilson +44 (0)7818 430877

Notes for Editors:

About Autolus

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus’ shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Perceptive Bioscience Investments Ltd. For further information please visit the Company’s website at:

About Syncona

Syncona LLP was founded in 2012 and operates as an evergreen investment company, taking an active role in identifying, developing and funding technologies with the potential to significantly impact the healthcare market of the future. Syncona can take the long view when necessary, able to concentrate investment into opportunities as technology is validated. Syncona is a subsidiary of the Wellcome Trust. For further information please visit the Company’s website at:

Record changed: 2018-06-14


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Autolus Therapeutics plc (Nasdaq: AUTL)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top